Insider Acquisition: Hornbeck Offshore Services, Inc. (HOS)’s director Kevin Meyers Purchased 7,731 shares; Last Week Lexicon Pharmaceuticals, Inc. (LXRX) Coverage

Hornbeck Offshore Services, Inc. (NYSE:HOS) Logo

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Ratings Coverage

Among 9 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Lexicon Pharmaceuticals had 20 analyst reports since August 4, 2015 according to SRatingsIntel. On Friday, February 23 the stock rating was downgraded by Needham to “Hold”. On Wednesday, February 14 the stock rating was downgraded by JP Morgan to “Underweight”. The rating was downgraded by J.P. Morgan to “Sell” on Wednesday, February 14. The company was maintained on Tuesday, August 1 by Cowen & Co. The firm earned “Buy” rating on Thursday, October 5 by Wedbush. As per Thursday, November 30, the company rating was maintained by Wedbush. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) earned “Sell” rating by Gabelli on Friday, September 18. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) earned “Buy” rating by Wedbush on Monday, March 12. Needham maintained the shares of LXRX in report on Monday, June 12 with “Buy” rating. The stock has “Buy” rating by Wedbush on Monday, August 7. See Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) latest ratings:

12/03/2018 Broker: Wedbush Rating: Buy New Target: $38.0 Maintain
23/02/2018 Broker: Needham Rating: Hold Downgrade
14/02/2018 Broker: J.P. Morgan Rating: Sell New Target: $10.0 Downgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Underweight Downgrade
30/11/2017 Broker: Wedbush Rating: Buy New Target: $38.0 Maintain

The stock increased 3.15% or $0.27 during the last trading session, reaching $8.84. About 543,574 shares traded. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has declined 43.19% since April 5, 2017 and is downtrending. It has underperformed by 54.74% the S&P500.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company has market cap of $933.43 million. The firm offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with SSA therapy in adults. It currently has negative earnings. The Company’s orally-delivered small molecule drug candidates under development comprise Sotagliflozin that is in Phase 3 clinical trials for use in the treatment of type 1 and type 2 diabetes; LX2761, which is in Phase 1 development for use in the treatment of diabetes; and LX9211 for use as a treatment for neuropathic pain.

Hornbeck Offshore Services, Inc., together with its subsidiaries, provides marine transportation, subsea installation, and accommodation support services to exploration and production, oilfield service, offshore construction, and the U.S. military customers. The company has market cap of $108.10 million. It operates offshore supply vessels , multi-purpose support vessels (MPSVs), and a shore facility to provide logistics support and specialty services to the offshore gas and oil exploration and production industry, primarily in the U.S. It has a 3.99 P/E ratio. Gulf of Mexico, Latin America, and internationally.

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.65, from 0.48 in 2017Q3. It improved, as 8 investors sold Hornbeck Offshore Services, Inc. shares while 15 reduced holdings. 10 funds opened positions while 16 raised stakes. 22.79 million shares or 16.86% less from 27.41 million shares in 2017Q3 were reported. Gsa Capital Prtn Limited Liability Partnership accumulated 116,048 shares. Alpine Glob Ltd Limited Liability Company accumulated 24,918 shares. California Pub Employees Retirement System, California-based fund reported 656,630 shares. Brandes Investment L P has invested 0% of its portfolio in Hornbeck Offshore Services, Inc. (NYSE:HOS). Raymond James Services Advsrs reported 25,900 shares. Manufacturers Life Com The stated it has 0% of its portfolio in Hornbeck Offshore Services, Inc. (NYSE:HOS). Deutsche Financial Bank Ag reported 82 shares. Cyrus Cap Partners Limited Partnership owns 3.58M shares. Bnp Paribas Arbitrage holds 0% or 2,508 shares. New York-based Caspian Capital Limited Partnership has invested 4.92% in Hornbeck Offshore Services, Inc. (NYSE:HOS). Northern Trust reported 0% of its portfolio in Hornbeck Offshore Services, Inc. (NYSE:HOS). Morgan Stanley invested in 35,455 shares or 0% of the stock. Dimensional Fund Lp owns 2.03 million shares. Invesco owns 0% invested in Hornbeck Offshore Services, Inc. (NYSE:HOS) for 566,289 shares. Schroder Investment Mgmt Group reported 0% stake.

Kevin Meyers, the director of Hornbeck Offshore Services Inc La made a surprising deal for 7,731 shares with an average stock price per share of $3.0 in the corporation, that are having a total value $23,270 U.S. Dollars. Kevin now owns 78,609 shares accounting for 0.21% of the Company’s market cap

The stock increased 0.69% or $0.02 during the last trading session, reaching $2.91. About 88,678 shares traded. Hornbeck Offshore Services, Inc. (NYSE:HOS) has declined 22.31% since April 5, 2017 and is downtrending. It has underperformed by 33.86% the S&P500.

Analysts await Hornbeck Offshore Services, Inc. (NYSE:HOS) to report earnings on May, 2. They expect $-0.73 earnings per share, up 3.95% or $0.03 from last year’s $-0.76 per share. After $-0.44 actual earnings per share reported by Hornbeck Offshore Services, Inc. for the previous quarter, Wall Street now forecasts 65.91% negative EPS growth.

Hornbeck Offshore Services, Inc. (NYSE:HOS) Institutional Positions Chart